Chikungunya future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 2: Line 2:
{{Chikungunya}}
{{Chikungunya}}


Please help WikiDoc by adding content here. It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
==Future Therapies==
{| style="border: 0px; font-size: 85%; margin: 3px;" align=center
|+
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|}}
! style="background: #4479BA; width: 160px;" | {{fontcolor|#FFF|Chloroquine}}
! style="background: #4479BA; width: 160px;" | {{fontcolor|#FFF|Ribavirin}}
! style="background: #4479BA; width: 160px;" | {{fontcolor|#FFF|6-Azauridine}}
! style="background: #4479BA; width: 160px;" | {{fontcolor|#FFF|Arbidol}}
! style="background: #4479BA; width: 160px;" | {{fontcolor|#FFF|Harringtonine}}
|-
| style="padding: 5px 5px; background: #DCDCDC;" | Assay type
| style="padding: 5px 5px; background: #F5F5F5;" |In vitro (vero cells)
| style="padding: 5px 5px; background: #F5F5F5;" |Human
| style="padding: 5px 5px; background: #F5F5F5;" |In vitro (vero cells)
| style="padding: 5px 5px; background: #F5F5F5;" |In vitro (vero and primary human fibroblast cells)
| style="padding: 5px 5px; background: #F5F5F5;" |In vitro (BHK21 cells)
|-
| style="padding: 5px 5px; background: #DCDCDC;" | Hypothesized target
| style="padding: 5px 5px; background: #F5F5F5;" | Disrupted endosome-mediated CHIKV internalization, possibly through the prevention of endosomal acidification.
| style="padding: 5px 5px; background: #F5F5F5;" |Can interact with the intracellular viral RNA production.
| style="padding: 5px 5px; background: #F5F5F5;" |Inhibition of orotidine monophosphate decarboxylase, an enzyme involved in the de novo biosynthesis of pyrimidine, cytidine, and thymidine.
| style="padding: 5px 5px; background: #F5F5F5;" |Inhibition of virus mediated fusion and blocking of the viral entry into the target cells through inhibition of glycoprotein conformational changes that are essential for the fusion process.
| style="padding: 5px 5px; background: #F5F5F5;" |Affects CHIKV RNA production inside the infected cell as well as viral protein expression such as the nsP3 and the E2 proteins.
|-
| style="padding: 5px 5px; background: #DCDCDC;" | Advantages
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #DCDCDC;" | Disadvantages
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #DCDCDC;" | References
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #FFF;" colspan="6"| <SMALL>Table adapted from </SMALL>
|-
|}


==References==
==References==

Revision as of 18:15, 18 June 2014

Chikungunya Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Chikungunya from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Chikungunya future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chikungunya future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chikungunya future or investigational therapies

CDC on Chikungunya future or investigational therapies

Chikungunya future or investigational therapies in the news

Blogs on Chikungunya future or investigational therapies

Directions to Hospitals Treating Chikungunya

Risk calculators and risk factors for Chikungunya future or investigational therapies

Future Therapies

Chloroquine Ribavirin 6-Azauridine Arbidol Harringtonine
Assay type In vitro (vero cells) Human In vitro (vero cells) In vitro (vero and primary human fibroblast cells) In vitro (BHK21 cells)
Hypothesized target Disrupted endosome-mediated CHIKV internalization, possibly through the prevention of endosomal acidification. Can interact with the intracellular viral RNA production. Inhibition of orotidine monophosphate decarboxylase, an enzyme involved in the de novo biosynthesis of pyrimidine, cytidine, and thymidine. Inhibition of virus mediated fusion and blocking of the viral entry into the target cells through inhibition of glycoprotein conformational changes that are essential for the fusion process. Affects CHIKV RNA production inside the infected cell as well as viral protein expression such as the nsP3 and the E2 proteins.
Advantages
Disadvantages
References
Table adapted from

References

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Chikungunya_future_or_investigational_therapies&oldid=979460"